118.77
0.47%
0.55
After Hours:
118.77
Biontech Se Adr stock is traded at $118.77, with a volume of 566.60K.
It is up +0.47% in the last 24 hours and up +34.63% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
See More
Previous Close:
$118.22
Open:
$117.3
24h Volume:
566.60K
Relative Volume:
0.61
Market Cap:
$28.20B
Revenue:
$2.91B
Net Income/Loss:
$-544.08M
P/E Ratio:
10.29
EPS:
11.5384
Net Cash Flow:
$2.51B
1W Performance:
+5.06%
1M Performance:
+34.63%
6M Performance:
+28.75%
1Y Performance:
+9.32%
Biontech Se Adr Stock (BNTX) Company Profile
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-05-24 | Initiated | Oppenheimer | Perform |
Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
Jul-14-23 | Initiated | HSBC Securities | Buy |
May-17-23 | Upgrade | Redburn | Neutral → Buy |
Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
Aug-17-22 | Initiated | Cowen | Market Perform |
Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Jul-06-22 | Resumed | Canaccord Genuity | Buy |
Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Oct-22-21 | Initiated | Deutsche Bank | Hold |
Oct-07-21 | Initiated | Jefferies | Hold |
Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
Jul-19-21 | Resumed | Wolfe Research | Outperform |
Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
May-18-21 | Initiated | Goldman | Neutral |
May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
Aug-03-20 | Resumed | Berenberg | Buy |
Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jan-22-20 | Downgrade | UBS | Buy → Neutral |
Nov-05-19 | Initiated | Wolfe Research | Outperform |
Nov-04-19 | Initiated | Berenberg | Buy |
Nov-04-19 | Initiated | BofA/Merrill | Buy |
Nov-04-19 | Initiated | Canaccord Genuity | Buy |
Nov-04-19 | Initiated | JP Morgan | Overweight |
Nov-04-19 | Initiated | SVB Leerink | Outperform |
Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
BioNTech SE ADR rises Monday, outperforms market - MarketWatch
BioNTech SE ADR (BNTX) can make a big difference with a little luck - SETE News
BioNTech SE ADR rises Friday, outperforms market - MarketWatch
BioNTech SE ADR rises Thursday, outperforms market - MarketWatch
Are Smart Investors Making the Right Decision? BioNTech SE ADR (BNTX) - SETE News
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
What Are You Thinking About Investing In BioNTech SE ADR (NASDAQ: BNTX) Stock? - Stocks Register
Results from BioNTech SE ADR (BNTX) show potential - US Post News
Financial Analysis: BioNTech SE ADR (BNTX)’s Ratios Unveil Key Insights - The Dwinnex
Discovery Capital Management LLC CT Invests $2.47 Million in BioNTech SE (NASDAQ:BNTX) - MarketBeat
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? - Benzinga
BioNTech SE ADR falls Friday, underperforms market - MarketWatch
BioNTech’s Omicron Vaccine Awaits EU Approval - TipRanks
BioNTech SE ADR falls Thursday, underperforms market - MarketWatch
Daily Market Movement: BioNTech SE ADR (BNTX) Sees a -7.29 Decrease, Closing at 115.62 - The Dwinnex
Royal Bank of Canada Reiterates Outperform Rating for Biogen (NASDAQ:BIIB) - MarketBeat
BioNTech price target raised to $150 from $95 at Deutsche Bank - TipRanks
Jefferies upgrades BioNTech SE ADR (BNTX) rating to a Buy - Knox Daily
Analyzing Trump Media & Technology Group Corp. (DJT) After Recent Trading Activity - Knox Daily
Monitoring Energous Corp (WATT) after recent insider movements - Knox Daily
Breaking down BNTX’s current quarter earnings estimates - US Post News
BioNTech SE ADR (NASDAQ:BNTX) Upgraded By JPMorgan - FXDailyReport.com
Here's Why Everyone's Talking About Summit Therapeutics - The Motley Fool
BioNTech SE ADR rises Monday, still underperforms market - MarketWatch
Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So. - The Motley Fool
A significant driver of top-line growth: BioNTech SE ADR (BNTX) - SETE News
Weekly Upgrades and Downgrades - MSN
BioNTech SE ADR (BNTX) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
BioNTech (NASDAQ:BNTX) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
BioNTech upgraded to Neutral from Underweight at JPMorgan - TipRanks
TD Cowen maintains Hold rating on BioNTech shares from TD Cowen - Investing.com
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar? - MSN
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar? - Yahoo Finance
Analysts Set BioNTech SE (NASDAQ:BNTX) Target Price at $109.09 - MarketBeat
Market Insights: BioNTech SE ADR (BNTX)’s Notable Drop of -1.35, Closing at 99.27 - The Dwinnex
BioNTech SE ADR (BNTX) Performance and Fundamentals Dashboard tells a completely different story - SETE News
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech - Benzinga
BioNTech SE ADR rises Tuesday, still underperforms market - MarketWatch
Is BNTX’s price to cash per share ratio a concern for investors? - US Post News
BioNTech SE ADR (BNTX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Why Is Moderna Stock Trading Higher On Monday? - Benzinga
BioNTech SE ADR outperforms market despite losses on the day - MarketWatch
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows - Benzinga
BNTX (BioNTech SE ADR) has impressive results - US Post News
Get in on BioNTech SE ADR’s (BNTX) buy-in window today! - SETE News
Kearny Financial Corp. [KRNY] Insider Activity: An Update for Investors - Knox Daily
BioNTech SE ADR rises Friday, still underperforms market - MarketWatch
First-ever global lung cancer vaccine trial kicks off in the UK - Mugglehead
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales - Benzinga
BioNTech SE ADR rises Wednesday, outperforms market - MarketWatch
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):